Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. Stock down.
AMRN earnings call for the period ending June 30, 2024.
Uncovering affordable breakthrough stocks under $10 in the portfolio can lead to high-price return opportunities. Here, the focus is on three such stocks, each demonstrating strong fundamentals that signal high upside potential. The first company’s top prospects include continued revenue growth, significant improvements in gross margins and successful strategic expansions. These position the company for robust future performance in the environmentally sustainable carbon products sector. On the o